Clinical twisters: Addressing CVA prophylaxis - This case study assesses the need for anticoagulation and the drugs of choice for prophylaxis against cerebrovascular accidents (strokes) in patients wi

ADVERTISEMENT

Clinical twisters: Addressing CVA prophylaxis
This case study assesses the need for anticoagulation and the drugs of choice for prophylaxis against cerebrovascular accidents (strokes) in patients with previous CVAs of different origins.


Health-System Edition



A 60-year-old, female, bilateral leg amputee has diagnoses including PVD, diabetes, COPD, and history of CVA. She is residing in a nursing home with 100% G-tube feeding and is dependent on a tracheostomy artificial respirator. In a recent hospital visit for a CVA she was given heparin IV and was discharged with SC Heparin 5000 units three times daily. The only other significant medications included insulin, metoprolol 25mg bid, and Combivent inhaler tid. The nursing home continued the heparin for more than three months and no bleeding complications were observed. No laboratory data were available for a baseline PTT from the hospital. No signs of other complications or thrombocytopenia were evident. How long can heparin be given at this SC dose without any coagulation monitoring and, if she is not a candidate for warfarin, what are the other alternatives?


Key
In this case, the patient has the continuing DVT risk factors of immobility and respiratory disease that warrant prophylaxis. The heparin 5000 units SC TID dose is appropriate and can be given long term if the DVT risk continues, which it will in this case. Of additional concern is a recent CVA. If this was of cardioembolic origin, then warfarin would be preferred, although there would be issues with control and monitoring in this patient's case. If the patient is non-cardioembolic, then aspirin 81 mg daily would be recommended for CVA prophylaxis. LDUH is not sufficient for CVA stroke prophylaxis, and not recommended by the ACCP Consensus Guidelines. In this patient, the combination of LDUH and daily ASA is warranted. Due to the addition of the daily ASA, we recommend getting a baseline CBC (including PLT count) so that monitoring can be performed to track changes in PLT and H/H. There is still a small risk of HIT with the long term use of LDUH, so routine PLT monitoring (i.e., CBC) at least every three to six months would be warranted.

Nancy L. Shapiro, Pharm.D., BCPS
Aimee Chevalier, Pharm.D.
Clinical Pharmacists, Antithrombosis Clinic
Clinical Assistant Professor, Dept. of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy

Drug Topics Issue
Drug Topics is a monthly news magazine, guided by a board of pharmacy leaders, reporting on all phases of community, retail, and health-system issues and trends. We cover managed care and professional, national, and state activities as well as new therapies involving prescription and OTC drugs.
ARCHIVES | RSS | E-NEWS | DIGITAL EDITION

ADVERTISEMENT

ADVERTISEMENT

Survey
Do you agree that pharmacists should have the authority to prescribe medications?
Yes
No
Yes
72%
No
28%
View Results

Modern Medicine logoDrug Topics archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting Drug Topics for fresh content, news, opinions, editor's blogs and more.



ADVERTISEMENT

Source: Health-System Edition,
Click here